
The fight against HIV has challenged scientists for decades. Understanding where the virus came from and how it evolved has been critical to advancing both research and clinical care. Supbio’s founder and Chief Scientist, Professor Tuofu Zhu, is a tenured professor at the University of Washington and Director of the Molecular Virology Laboratory. His work is widely recognized for identifying one of the earliest known HIV-1 strains. In the early 1980s, researchers at the U.S. Centers for Disease Control examined a collection of African blood samples originally collected in 1959. Several samples were suspected to contain HIV, but available clinical and immunological methods could not confirm infection. Over the following years, these samples were sent to leading molecular biology laboratories around the world for analysis, yet none were able to detect the virus. In 1995, the remaining samples were distributed to two laboratories for further investigation, including Professor Zhu’s laboratory at the University of Washington. After years of research, Professor Zhu developed an ultra sensitive PCR method capable of detecting extremely small quantities of viral genetic material across different viral variants. Using this approach, his team successfully detected HIV-1 genetic sequences in the samples. Genetic analysis confirmed that the virus dated back to 1959, making it the oldest documented HIV-1 sample at the time. Evolutionary studies further suggested that HIV-1 entered the human population around 1920 in Central Africa. These findings significantly expanded scientific understanding of the early history of HIV. The research was published in Nature in 1998 and received widespread international media coverage, including reports from USA Today, The New York Times, and the Chicago Sun-Times.
Building on decades of research, Professor Zhu later developed an ultra sensitive quantitative detection technology designed to measure extremely small amounts of viral genetic material. Leading scientists in precision medicine recognized the importance of this work and encouraged its translation into clinical applications for major diseases such as infectious diseases and cancer. With the support of clinical experts and research institutions, Supbio was established to bring this technology from the laboratory into real world medical practice.
Today, Supbio applies Microscale-Precision Technologies to support early diagnosis, treatment monitoring, and research aimed at curing major diseases. The company’s mission is to advance precision diagnostics and contribute to global progress in infectious disease control and cancer care.